Intranasal esketamine and the dawn of precision psychiatry
- PMID: 34320126
- PMCID: PMC9041972
- DOI: 10.1590/1516-4446-2021-0031
Intranasal esketamine and the dawn of precision psychiatry
Conflict of interest statement
FDG has received personal fees from Pfizer and Janssen-Cilag. ALTL has received consulting fees from Janssen Pharmaceutical, Daiichi Sankyo, Cristalia Produtos Químicos e Farmacêuticos, Pfizer, Mantecorp Indústria Química e Farmacêutica, Libbs Farmacêutica, FQM Farma, and Sanofi-Aventis; and has received research fees from Janssen Pharmaceutical, Eli Lilly, H. Lundbeck A/S, Servier Laboratories, Biophytis, Novo Nordisk, Genentech, Hoffman-La Roche, FQM Farma, and Forum Pharmaceuticals. LCQ has received consulting fees from Allergan, Abbot, Cristalia, Janssen Pharmaceutical, and Lundbeck; and has received research fees from Janssen Pharmaceutical. FK has received personal fees from Daiichi Sankyo and Janssen-Cilag. The other authors report no conflicts of interest.
References
-
- Kennedy SH, Lam RW, McIntyre RS, Tourjman SV, Bhat V, Blier P, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. Pharmacological treatments. Can J Psychiatry. 2016;61:540–60. - PMC - PubMed
-
- Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps. Am J Psychiatry. 2006;163:1905–17. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources